Abstract
Venom immunotherapy (VIT) is highly effective in patients with Hymenoptera venom allergy (HVA), with a capacity to protect against reactions to stings that lasts even after its cessation after a recommended duration of at least 5 years.1 However, in patients with severe initial systemic reactions and elevated baseline serum tryptase (which is currently estimated as >11.4 mcg/L) or mast cell disorders, VIT may be less protective, requiring an increase in maintenance common dosage of 100 mcg up to 200 mcg.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
